Dynavax


William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015

2014 has been an eventful year on Wall Street. Now that the year is coming to an end, what stocks should investors be …

William Blair Maintains Outperform On Dynavax Following Initiation Of Phase I/II Study In B-cell Lymphoma

In a research report issued today, William Blair analyst Katherine Xu maintained an Outperform rating on Dynavax Tech. (NASDAQ:DVAX) with a $4 price …

William Blair Reiterates Outperform Rating For Dynavax

In a research note released this morning, William Blair reiterated coverage on Dynavax Technologies Corporation (DVAX) with an Outperform rating and a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts